Ximelagatran, melagatran dosage in severe renal impairment

By  

Inpharma, Vol. 1, Iss. 1400, 2003-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

No Influence of Obesity on the Pharmacokinetics and Pharmacodynamics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran

By Sarich T.C.  

Clinical Pharmacokinetics, Vol. 42, Iss. 5, 2003-01 ,pp. : 485-492

Adis International

Access to resources Recommend Favorite

No Influence of Ethnic Origin on the Pharmacokinetics and Pharmacodynamics of Melagatran Following Oral Administration of Ximelagatran, a Novel Oral Direct Thrombin Inhibitor, to Healthy Male Volunteers

By Johansson L.C.   Andersson M.   Fager G.   Gustafsson D.   Eriksson U.G.  

Clinical Pharmacokinetics, Vol. 42, Iss. 5, 2003-01 ,pp. : 475-484

Adis International

Access to resources Recommend Favorite

No Influence of Mild-To-Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor

By Wåhlander K.   Eriksson-Lepkowska M.   Frison L.   Fager G.   Eriksson U.G.  

Clinical Pharmacokinetics, Vol. 42, Iss. 8, 2003-01 ,pp. : 755-764

Adis International

Access to resources Recommend Favorite

Comparable Pharmacokinetics and Pharmacodynamics of Melagatran in Japanese and Caucasian Volunteers after Oral Administration of the Direct Thrombin Inhibitor Ximelagatran

By Wernevik Linda C.  

Clinical Pharmacokinetics, Vol. 45, Iss. 1, 2006-01 ,pp. : 85-94

Adis International

Access to resources Recommend Favorite